Raymond James Starts Climb Bio (CLYM) at Strong Buy

Raymond James analyst Christopher Raymond initiates coverage on Climb Bio (NASDAQ: CLYM) with a Strong Buy rating and a price target of $25.00.

The analyst comments "Initiating Coverage of CLYM shares with a Strong Buy rating, $25 price target. We think the company’s two lead assets: CLYM116 (an anti-APRIL sweeping antibody in development for IgAN), and budoprutug (budo) (an anti-CD19 antibody in development for a variety of rare renal/ autoimmune indications) are poised for significant value creation as important data cards turn over throughout 2026. Specifically, we anticipate CLYM116 will have initial P1 HV data mid-2026, which should provide meaningful evidence around this drug’s TPP. Next up, budoprutug will have three POC readouts (in pMN, ITP and SLE) 2H26. For our part, we only model pMN (primary membranous nephropathy) for this drug, and we anticipate meaningful indications of activity should de-risk this program, creating another inflection opportunity for the stock. Between these two assets, we model U.S. revenue of $205M, $423M, $858M, $1,318M, $1,806M, and $2,173M for FY31-FY36, respectively."

For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.

Shares of Climb Bio closed at $7.25 yesterday.

You May Also Be Interested In

• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• Natera (NTRA) PT Raised to $270 at BTIG
• TD Cowen Starts Nkarta Inc. (NKTX) at Buy